

**Amendments to the claims**

Claims 1-17 (canceled)

Claim 18 (currently amended): A method of treating bone loss in a patient suffering from an estrogen dependent disorder and receiving 4-[d-(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]-benzonitrile (letrozole) an aromatase inhibitor comprising administering to said patient an effective amount of a 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof.

Claim 19 (currently amended): A method of treating cancer treatment-related bone loss in a postmenopausal woman with ER+ and/or PR+ breast cancer receiving 4-[d-(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]-benzonitrile (letrozole) an aromatase inhibitor as adjuvant therapy comprising administering to said postmenopausal woman an effective amount of a 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof.

Claims 20-22 (cancelled)

Claim 23 (currently amended): The method according to claim 18 wherein the 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof is administered once every six months.

Claim 24 (currently amended): A method of treating bone loss caused by the treatment with 4-[d-(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]-benzonitrile (letrozole) an aromatase inhibitor of a disease or condition which responds to aromatase inhibition comprising administering to a patient in need of such treatment an effective amount of 4-[d-(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]-benzonitrile (letrozole) or a pharmaceutically acceptable salt thereof and an effective amount of a 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof.

Claim 25 (cancelled)